Day: February 26, 2025

Correction: Added a missing attachment in the Swedish version. Bank of Åland PlcAnnual Financial ReportFebruary 26, 2025, 9.30 EET The 2024 Annual Report of the Bank of Åland Plc has been publishedThe Annual Report for 2024 of the Bank of Åland Plc (Ålandsbanken Abp), including the 2024 corporate governance report, was published today in Swedish and English. The Compensation Report and the Capital and Risk Management Report were published as separate documents at the same time.  The financial reports in Swedish are being published in compliance with European Single Electronic Format (ESEF) reporting requirements. In line with ESEF requirements, the primary portions of the consolidated financial statements have been marked up with XBRL tags. The authorised public accounting company KPMG Oy has provided an independent auditors’ affidavit...

Press Release Nokia launches MX Context to accelerate Industry 4.0 with AI-powered contextual awareness suites #MWC25MX Context generates actionable insights to support intelligent automation for Industry 4.0 use cases. The solution uses sensor fusion and AI to interpret sensor data that helps enterprises improve their operational environment by eliminating data silos, optimizing resources, as well as enhancing worker safety. Launches with two use case suites, tracking and positioning and worker safety, that bring multi-modal sensor fusion and AI inferencing for operational technology.26 February 2025Espoo, Finland – Nokia today announced MX Context, a new solution that leverages sensor fusion technology to deliver AI-powered contextual awareness for industrial enterprises. Integrated into the Nokia Edge Compute and AI platform for...

Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturity Offering priced at 1.75% interest rate and 45% conversion premiumPALO ALTO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $500 million aggregate principal amount of 1.75% convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, the Company granted the initial purchasers an option to purchase up to an additional $75 million aggregate principal amount of notes. The sale of the notes is expected to close on...

Company Announcement No 08/202526 February 2025 Sydbank’s 2024 Annual Report Highly satisfactory profit thanks to all-time high core income Core income has risen to a new all-time high level of DKK 7,227m from the record-level of DKK 7,071m in 2023. The increase is mainly attributable to a rise in income from asset management due to a significant increase in capital under management. The Sydbank Group’s 2024 financial statements show a profit before tax of DKK 3,645m compared to DKK 4,281m in 2023. The decrease of DKK 636m is primarily attributable to impairment charges, which are DKK 622m higher in 2024 than in 2023. Profit before tax equals a return on equity of 24.6%. Profit for the year is DKK 2,762m against DKK 3,342m in 2023, equal to a return on average equity after tax of 18.6%. At the beginning of 2024 profit after tax was projected...

2024 organic pro forma sales growth of 8%, with pro forma adjusted EBITDA margin of 36.1%. 2025 outlook of 5-8% organic pro forma sales growth and 37-38% adjusted EBITDA margin.   2024 organic pro forma sales growth of 8% (Q4: 7%) and 8% on IFRS reported basis (Q4 7%). Food & Health Biosolutions at 7%, and Planetary Health Biosolutions at 9%. 2024 pro forma adjusted EBITDA margin of 36.1% (2H 36.8%), with 35.2% for Food & Health Biosolutions and 36.8% for Planetary Health Biosolutions. 2024 adjusted EBITDA margin on IFRS reported base of 36.2% (2H 36.8%). 2024 pro forma cash flow from operating activities at EUR 1,032.5 million, including the positive one-off item in H1. 2024 contribution from cost synergies at ~1pp on pro forma adjusted EBITDA margin at an 80% run rate of the 3-year EUR 80-90m target. Net debt/EBITDA at 1.4x...